Genix PharmaceuticalsGENPF EV-to-FCF is -21.17 as of Jul. 01, 2026. The stock has 3 warning signs investors should review. Among 558 Drug Manufacturers companies, Genix Pharmaceuticals ranks worse than 179211.29% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genix Pharmaceuticals's Enterprise Value is $1.40 Mil.
Genix Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.07 Mil. Therefore, Genix Pharmaceuticals's EV-to-FCF for today is -21.17.
The historical rank and industry rank for Genix Pharmaceuticals's EV-to-FCF or its related term are showing as below:
GENPF'
s EV-to-FCF Range Over the Past 10 Years
Min: -3174.69 Med: -44.34 Max: 177.79
Current: -21.8
During the past 13 years, the highest EV-to-FCF of Genix Pharmaceuticals was 177.79. The lowest was -3174.69. And the median was -44.34.
GENPF's EV-to-FCF is ranked worse than 100% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs GENPF: -21.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genix Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Genix Pharmaceuticals's share price for today is $0.0151.
Genix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genix Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Genix Pharmaceuticals's EV-to-FCF falls into.
Genix Pharmaceuticals's current Enterprise Value is $1.40 Mil.
Genix Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genix Pharmaceuticals (GENPF) has a EV-to-FCF of -21.17 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genix Pharmaceuticals and its competitors. According to the industry distribution chart, Genix Pharmaceuticals ranks #999999 out of 558 companies in the Drug Manufacturers industry.
Is Genix Pharmaceuticals' EV-to-FCF too high?
Genix Pharmaceuticals' current EV-to-FCF is -21.17. Based on the distribution chart, Genix Pharmaceuticals ranks #999999 out of 558 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Genix Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #999999 out of 558 companies for EV-to-FCF. This places Genix Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current EV-to-FCF is -21.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current EV-to-FCF of -21.17. The current EV-to-FCF is -21.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current EV-to-FCF is -21.17 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENPF has been successfully added to your 